 This was a multicenter, open label, randomized, controlled, safety trial in subjects aged 6-75 years with a diagnosis of moderate to severe, persistent asthma. A total of 1899 subjects were randomized 2:1 to either the active treatment group or the control group. Upon successful completion of the screening period 2 weeks, each subject entered the 24 week study. 